Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy
Long-term survival in patients with newly diagnosed primary central nervous system lymphoma treated with dexamethasone, etoposide, ifosfamide and carboplatin chemotherapy and whole-brain radiation therapy
复制标题
DOI：
10.3109/10428194.2011.596967
复制
发表时间：
2011-11-01
影响因子：
2.6
通讯作者：
Wakabayashi, Toshihiko
中科院分区：
文献类型：
--
作者：
Motomura, Kazuya;Natsume, Atsushi;Wakabayashi, Toshihiko
本研究旨在评价DeVIC（地塞米松、依托泊苷、异环磷酰胺和卡铂）化疗方案治疗原发性中枢神经系统淋巴瘤（PCNSL）的安全性和有效性。我们回顾性研究了21例新诊断的PCNSL患者，他们接受了DeVIC化疗，随后接受了全脑放射治疗（WBRT）。所有患者的中位无进展生存期（PFS）为37.4个月，中位总生存期（OS）为47.8个月。值得注意的是，DeVIC化疗后达到完全缓解（CR）的患者（49.0个月）的中位OS持续时间显著长于未达到CR的患者（12.8个月）。此外，我们发现初始DeVIC化疗的总体反应率为95.2%。未观察到给药相关死亡。我们的研究调查了DeVIC化疗在PCNSL患者中的疗效，并发现其在这些患者中产生了有利的生存结局，从而避免了进一步研究其作为PCNSL的治疗措施。
In the present study, we aimed to evaluate the safety and efficacy of DeVIC (dexamethasone, etoposide, ifosfamide and carboplatin) chemotherapy for the treatment of patients with primary central nervous system lymphoma (PCNSL). We retrospectively examined 21 patients with newly diagnosed PCNSL who received DeVIC chemotherapy followed by whole-brain radiation therapy (WBRT). The median progression-free survival (PFS) in all patients was 37.4 months and the median duration of overall survival (OS) was 47.8 months. Notably, the median duration of OS was significantly longer in patients who achieved a complete response (CR) after DeVIC chemotherapy (49.0 months) than in those without CR (12.8 months). Furthermore, we found that the overall response rate to the initial DeVIC chemotherapy was 95.2%. No treatment-related deaths were observed. Our study investigated the efficacy of DeVIC chemotherapy in PCNSL patients, and found it to result in favorable survival outcomes in these patients, thus warranting further investigation of it as a therapeutic measure against PCNSL.